Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
AuthorsBrooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA,
JournalCancer
PubMed ID21523723
'Treatment options for patients with advanced head and neck squamous cell carcinoma (HNSCC) are scarce. This phase 2 study was conducted to evaluate the safety, tolerability, pharmacokinetics, and efficacy of dasatinib in this setting. Patients with recurrent and/or metastatic HNSCC after platinum-based therapy were treated with dasatinib either orally or ... More